Table 2 Relationship between control medications and exacerbation severity

(A) LTRA use and exacerbation severity for RV/EV-positive patients

LTRA use

No LTRA use

p value

Mild, N (%)

3 (2.3)

1 (0.8)

0.39

Moderate, N (%)

47 (35.9)

64 (48.9)

Severe, N (%)

6 (4.6)

10 (7.6)

(B) LTRA use and exacerbation severity for RV/EV-negative patients

LTRA use

No LTRA use

p value

Mild, N (%)

2 (3.5)

1 (1.7)

0.74

Moderate, N (%)

20 (34.5)

26 (44.8)

Severe, N (%)

4 (6.9)

5 (8.6)

(C) ICS use and exacerbation severity for RV/EV-positive patients

ICS use

No ICS use

p value

Mild, N (%)

4 (3.1)

0

 < 0.001

Moderate, N (%)

23 (17.6)

88 (67.2)

Severe, N (%)

1 (0.8)

15 (11.5)

(D) ICS use and exacerbation severity for RV/EV-negative patients

ICS use

No ICS use

p value

Mild, N (%)

0

3 (5.2)

0.51

Moderate, N (%)

14 (24.1)

32 (55.2)

Severe, N (%)

3 (5.2)

6 (10.3)